TY  - GEN
AU  - Reyners,A K L
AU  - de Munck,L
AU  - Erdkamp,F L G
AU  - Smit,W M
AU  - Hoekman,K
AU  - Lalisang,R I
AU  - de Graaf,H
AU  - Wymenga,A N M
AU  - Polee,M
AU  - Hollema,H
AU  - van Vugt,M A T M
AU  - Schaapveld,M
AU  - Willemse,P H B
TI  - A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study
SN  - 1569-8041
PY  - 2013///0429
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Carboplatin
KW  - administration & dosage
KW  - Carcinoma, Ovarian Epithelial
KW  - Celecoxib
KW  - Cyclooxygenase 2 Inhibitors
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Fallopian Tube Neoplasms
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neoplasms, Glandular and Epithelial
KW  - Ovarian Neoplasms
KW  - Peritoneal Neoplasms
KW  - Pyrazoles
KW  - Sulfonamides
KW  - Taxoids
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mds107
ER  -